New Study Reveals Path to Strengthen MedTech Innovation for Non-Communicable Diseases in Least Developed Countries

A landmark collaboration between the UN Technology Bank, Medtronic, and WIPO identifies actionable strategies to build medical technology ecosystems in Bangladesh and Rwanda, offering a blueprint for the world’s most vulnerable nations.

Non-communicable diseases (NCDs) now account for more than 70% of global deaths, yet the burden falls disproportionately on least developed countries (LDCs) where healthcare infrastructure remains fragile. A groundbreaking study released this month by the UN Technology Bank, global medical technology leader Medtronic, and the World Intellectual Property Organization (WIPO) provides the first in-depth analysis of how strengthening medical technology innovation ecosystems can address this crisis.

[IMAGE: Infographic showing NCD mortality vs. infectious disease mortality in LDCs versus high-income countries, with clear percentage breakdowns and regional comparisons]

The Silent Crisis: Why NCDs Demand a MedTech Revolution in LDCs

The dual burden of infectious and chronic diseases has stretched health systems in LDCs to breaking points. While malaria, tuberculosis, and HIV/AIDS continue to claim lives, cardiovascular diseases, diabetes, hypertension, and cancers are rising rapidly. The World Health Organization estimates that NCDs kill 41 million people annually, with over three-quarters of these deaths occurring in low- and middle-income countries.

Medical technology—from portable diagnostic devices to affordable treatment equipment—offers a critical lever for early detection, monitoring, and management of NCDs. Yet the innovation ecosystems needed to develop, adapt, and scale such technologies remain fragmented or entirely absent in LDCs. Local innovators struggle with limited R&D funding, weak regulatory pathways, and inadequate intellectual property (IP) frameworks. Global technology transfer mechanisms often bypass these markets due to perceived low returns.

The new study, titled “Building Medical Technology Innovation Ecosystems to Address Non-Communicable Diseases in Least Developed Countries,” fills a significant research gap. Rather than offering generic recommendations, it provides granular, evidence-based analysis of what works—and what doesn’t—in two distinct LDC settings.

Inside the Study: A Tripartite Collaboration for Real-World Impact

The research represents an unusual convergence of expertise. The UN Technology Bank, established specifically to strengthen LDC science and technology capacity, brought its deep understanding of local constraints. Medtronic contributed decades of experience in developing and delivering medical devices globally. WIPO provided specialized knowledge on intellectual property mechanisms that can either accelerate or block technology diffusion.

Fieldwork was conducted intensively in Bangladesh and Rwanda between 2023 and 2024. These countries were selected not merely for convenience but for their contrasting characteristics that illuminate different dimensions of the MedTech challenge.

Bangladesh, with its population density of over 1,200 people per square kilometer and a growing middle class, faces a rapidly escalating diabetes and hypertension epidemic. Its domestic medical device sector, centered largely on assembly of basic items like syringes and surgical gloves, is now exploring more sophisticated product development. Rwanda, by contrast, has earned global recognition for its state-driven health digitization—including drone networks delivering blood supplies and a national electronic medical record system—yet its startup ecosystem remains small.

[IMAGE: Photo of a research team meeting with local health workers in a clinic in a rural setting, with notebooks and portable devices visible; no identifiable individuals]

In both countries, the research team conducted over 150 interviews with local innovators, regulators, clinicians, hospital administrators, and patient groups. They also analyzed medical device registrations, funding flows, and patent filings. This primary data collection allowed the study to move beyond high-level policy talk to identify specific bottlenecks in R&D, regulation, financing, and market access.

Bangladesh and Rwanda: Two Laboratories for MedTech Ecosystems

Bangladesh: Frugal Innovation and Last-Mile Distribution

Bangladesh’s challenge is scale. With 170 million people, many living in remote riverine areas, delivering diagnostic and treatment devices to underserved populations requires radical cost reduction and distribution innovation. The study found several promising homegrown initiatives. For example, Bangabandhu Sheikh Mujib Medical University has developed low-cost glucometers and blood pressure monitors manufactured locally, reducing prices by 60% compared to imported equivalents.

However, these innovations face a critical barrier: lack of clinical validation infrastructure. Without local testing facilities compliant with international standards, products cannot obtain regulatory approvals needed for export or even for wide domestic reimbursement schemes. The study documents how a single validated diagnostic device for diabetic retinopathy took nearly three years to navigate local regulatory processes, during which time the technology became outdated.

Another barrier identified in Bangladesh is weak intellectual property protection for local adaptations. Innovators who modify imported technologies for local conditions—such as creating solar-powered infusion pumps for off-grid clinics—often lack the resources to file patents or enforce licensing agreements. The study shows how this deters both local entrepreneurs and potential foreign partners from investing.

Rwanda: Policy-Driven Digitization and Startup Dynamics

Rwanda’s experience is almost the mirror image. The government has aggressively promoted health technology through its national digital health strategy, which includes a central electronic medical records platform and partnerships with drone logistics companies like Zipline. This creates demand pull for new devices that can integrate with digital systems.

Yet the study reveals that Rwanda’s small but vibrant startup scene faces different obstacles. Local innovators struggle to access global supply chains for components. One startup developing a portable ECG device had to source microprocessors from China, sensors from Germany, and casing from India—each step incurred tariffs, shipping delays, and customs bureaucracy that took months. The fragmented import regime effectively penalizes local assembly compared to importing finished devices.

Common challenges across both countries include weak IP protection, lack of local clinical validation infrastructure, and difficulty accessing global supply chains. The study argues that these are not merely technical issues but reflect deeper ecosystem gaps—in skills training, long-term financing, and coordinated policy across health, trade, and innovation ministries.

[IMAGE: Side-by-side images: left shows a Bangladeshi medtech workshop with workers assembling blood pressure monitors; right shows a Rwandan drone landing pad next to a health clinic with medical supply packages]

The Hidden Economic Logic: IP, Technology Transfer, and Market Shaping

A central finding of the study is that intellectual property, often portrayed as a barrier to technology access in poor countries, can be strategically leveraged to accelerate local innovation. The report documents several cases where voluntary licensing agreements—similar to those used in HIV/AIDS drug access—enabled local firms to manufacture patented diagnostic devices with technology transfer support. In Bangladesh, a joint venture between a local manufacturer and a South Korean company allowed production of low-cost dialysis machines, with royalties capped at 5% and technical training provided.

Medtronic’s involvement in the study is notable because it represents a shift among large medical technology firms. Traditionally, these companies focused on high-margin markets in developed countries. However, the report shows that with appropriate IP frameworks, companies can enter LDC markets through socially responsible licensing while protecting their core technologies. The study identifies four models: open innovation platforms (where companies share non-core patents), technology transfer partnerships, public procurement guarantees that lower investment risk, and tiered pricing combined with local value addition.

WIPO’s contribution included analysis of patent landscapes for NCD-related medical technologies. The study found that in Bangladesh and Rwanda, only 2% of patents related to diabetes or cardiovascular devices were filed by local entities. This does not mean local innovation is absent—rather, innovators often rely on trade secrets or informal copying. The report recommends establishing patent informatics centers that help local firms understand freedom-to-operate and identify expired patents they can legally build upon.

Financing and Sustainability: Beyond Grant Dependence

The study’s economic analysis is particularly revealing. Most MedTech startups in both countries rely on short-term grants from international donors—a model that rarely supports product development from concept to market. One Rwandan entrepreneur described “pilot project fatigue”: receiving numerous grants for prototypes that never reach patients because no funding covers the final regulatory approval and distribution scale-up.

The report proposes blended finance mechanisms that combine catalytic grants with patient capital from impact investors, health system cost savings, and performance-based payments. For instance, if a locally made diagnostic device reduces hospital readmissions for diabetic patients, the savings could be shared between the manufacturer and the public health insurer. Bangladesh’s central bank has already expressed interest in creating a health technology innovation fund modeled on this approach.

Recommendations for Policymakers, Investors, and Health Leaders

The study distills its findings into six actionable recommendations:

1. Establish national MedTech innovation hubs that provide shared clinical validation facilities, regulatory guidance, and connection to global supply chains.
2. Create tiered regulatory pathways that allow low-risk devices to enter the market faster without compromising safety, as is already done for some devices in India and South Africa.
3. Develop IP education and support services for local innovators, including patent clinics and template licensing agreements.
4. Launch public procurement commitments that guarantee a minimum purchase volume for locally manufactured devices meeting quality standards, reducing investment risk.
5. Design blended finance instruments combining grants, concessional loans, and outcomes-based payments, with a target of mobilizing $100 million over five years in each country.
6. Foster cross-border learning networks between LDCs, leveraging the similarities in infrastructure and disease burden rather than forcing models from high-income countries.

The Path Forward: From Pilot to Systemic Change

The study’s timing is critical. The global NCD epidemic is projected to accelerate in LDCs over the next decade as populations age and lifestyles change. Without affordable, appropriate medical technology, these countries face decades of preventable suffering and economic loss from premature deaths and disability.

The UN Technology Bank, Medtronic, and WIPO have committed to follow-up actions, including creating an online platform to share best practices and connecting LDC innovators with potential partners. Medtronic has also announced a new open-innovation challenge specifically for diagnostics suited to resource-limited settings, with a focus on Bangladesh and Rwanda.

“This is not about charity but about building sustainable ecosystems,” said Dr. Olusola Owolabi, a lead researcher on the study. “The world cannot afford to keep designing medical technologies for the richest 20% of the population. The innovations that emerge from LDCs, born out of necessity and constraint, have global relevance. We just need to remove the barriers that keep them trapped in pilot phases.”

As NCDs continue their silent march into the most vulnerable communities, this study offers something rare: a concrete, evidence-based roadmap for turning medical technology innovation from a distant aspiration into a daily reality. For the millions facing diabetes, hypertension, and heart disease in Bangladesh, Rwanda, and beyond, the time to act is now.

[IMAGE: A photorealistic scene in a rural village in a developing country: a local health worker using a portable, modern medical diagnostic device under a shade tree, with a thatched-roof clinic in the background. Sunlight filters through leaves, highlighting the device screen. Warm, hopeful tone.]